ArticleClinical case reports2026
Pseudotumor Cerebri Syndrome and Essential Thrombocythemia: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudotumor cerebri syndrome (PTCS) is characterized by elevated intracranial pressure in the absence of intracranial mass lesions, structural abnormalities, or infectious conditions. Although the exact pathogenesis of PTCS remains largely elusive, it is increasingly recognized as a multifactorial condition. Identifying secondary contributors is essential for guiding etiology-specific management and achieving an optimal treatment response. Essential thrombocythemia (ET) is a myeloproliferative neoplasm involving sustained thrombocytosis and an elevated risk of thrombotic complications. We present a case of PTCS associated with ET. In this instance, significant symptomatic relief coincided with the initiation of antiplatelet and cytoreductive therapy. This clinical trajectory suggests a potential synergistic association between ET-related hematologic changes and the development of PTCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.